SONN missed EPS expectations by 10.03%
Feb 13, 2025, 11:34 PM
0.00%
What does SONN do
Sonnet BioTherapeutics Holdings, a clinical stage biotech based in Princeton, New Jersey, specializes in biologic medicines and has developed the FHAB technology for improved drug delivery in cancer treatment. Its lead assets include SON-1010 for solid tumors and SON-080 for chemotherapy-induced peripheral neuropathy.
Sonnet BioTherapeutics Holdings (SONN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sonnet BioTherapeutics Holdings's actual EPS was -$1.56, missing the estimate of -$1.42 per share, resulting in a -10.03% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.